Perioperative treatment with octreotide minimizes technical complications after enteric conversion of bladder‐drained pancreas transplants

Abstract

We review our experience with enteric conversion of previously bladder-drained pancreas transplants (PTx) using a short perioperative course of octreotide (OCT). Between July 1994 and December 2001, 45 consecutive primary bladder-drained PTx were performed. Immunosuppression consisted of a combination of tacrolimus, mycophenolate mofetil and steroids after induction with monoclonal or polyclonal antibodies. A total of 16 patients underwent enteric conversion at an average of 3 months after the initial transplant. Each patient received OCT perioperatively. We report no technical complications with the exception of one superficial wound infection and good early and late PTx survival rates. Perioperative treatment with octreotide is well tolerated and may reduce technical complications while performing enteric conversion of previously bladder-drained PTx.

Enteric conversion after pancreatic transplantation: resolution of symptoms and long‐term results

“…Furthermore, a systematic review of the literature is not available. Tables 7 and 8 give an overview of the results of different centers throughout the past 15 yr. With exception of one publication (47) in which the authors reported a high conversion rate of 39.5% that was explained with a fairly liberal and early conversion policy (on average thee months after SPK), the overall incidence of EC varied between 12% and 26% of BD patients. This variation is easily explained by the time dependence of this variable as displayed in Fig.…”

“…The topic of EC has been addressed within some retrospective studies (12–16, 39–41, 45–47). In‐depth analysis of postoperative complications and long‐term follow‐up of patients, however, has rarely been reported.…”

“…Postoperative leakage as a major surgical complication, however, was reported in 8–20% and was 12.5% in the present population (13–16, 39, 46). Only two minor studies did not show any postoperative leakage (40, 47). Early postoperative graft loss (<90 d) must be considered in a significant number of patients.…”

Μορφολογική, Βιοχημική Και Μοριακή Μελέτη Της Προστατευτικής Δράσης Των Μορίων U-74389g (Λαζαροειδές), Της Ερυθροποιητίνης, Της Συλδεναφίλης Και Της Οκτρεοτίδης Στην Συντήρηση Ήπατος Για Μεταμόσχευση

“…• Κανένα δεν έχει δοκιμαστεί, ειδικά μάλιστα στα προτεινόμενα στάδια μελέτης, σε μεγάλα ζωικά πρότυπα 101 .…”